% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lozanovski:127974,
      author       = {V. J. Lozanovski and P. Houben and U. Hinz and T. Hackert
                      and I. Herr$^*$ and P. Schemmer},
      title        = {{P}ilot study evaluating broccoli sprouts in advanced
                      pancreatic cancer ({POUDER} trial) - study protocol for a
                      randomized controlled trial.},
      journal      = {Trials},
      volume       = {15},
      number       = {1},
      issn         = {1745-6215},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2017-03996},
      pages        = {204},
      year         = {2014},
      abstract     = {Pancreatic ductal adenocarcinoma (PDA) is one of the most
                      aggressive malignancies with marked resistance to chemo- and
                      radiotherapy. PDA-cancer stem cells (CSCs) are not targeted
                      by current therapies and may be a reason for poor prognosis.
                      Studies indicate that diets rich in cabbage, broccoli, and
                      cauliflower offer cancer preventative and therapeutic
                      benefits. Recent experimental studies have confirmed these
                      findings and demonstrated that isothiocyanate, sulforaphane,
                      and the polyphenol, quercetin, effectively reduced tumor
                      growth and enhanced the sensitivity of the cancer cells to
                      current chemotherapeutics. The aim of the present study is
                      to test the feasibility of a randomized controlled trial on
                      the application of freeze-dried broccoli sprouts in patients
                      with advanced PDA.The study is designed as a prospective
                      randomized, double-blinded pilot trial with a treatment and
                      a placebo-controlled arm in a single center setting. A total
                      number of forty patients (18 years or older) in two parallel
                      groups with advanced, surgically non-resectable PDA under
                      palliative chemotherapy are planned for recruitment.
                      Patients in the treatment group will receive fifteen
                      capsules of the study substance per day (90 mg of active
                      sulforaphane) during the chemotherapy treatment course.
                      Patients in the placebo group will receive the same capsule
                      size and portion distribution with inactive substances
                      (mainly methylcellulose). The follow-up duration is one
                      year. Feasibility of the study substance, adverse effects,
                      and patient compliance, as well as levels of serum tumor
                      markers (CEA, CA 19-9), quality of life, and patient overall
                      survival rates will be assessed at defined points of
                      time.The POUDER trial is expected to transfer promising
                      experimental and epidemiological data into a clinical pilot
                      study to assess the effectiveness of broccoli sprout
                      extracts in the treatment of advanced PDA. The study
                      objectives will provide data on the clinical feasibility and
                      acceptability of a supportive treatment option accompanying
                      palliative chemotherapy. Based on these results, future
                      clinical studies to create further evidence in this field
                      are possible.The POUDER trial has been registered at
                      ClinicalTrials.gov with an ID NCT01879878 and WHO with an ID
                      U1111-1144-2013 on June 13th 2013.},
      keywords     = {Antineoplastic Agents (NLM Chemicals) / Biomarkers, Tumor
                      (NLM Chemicals)},
      cin          = {G403},
      ddc          = {610},
      cid          = {I:(DE-He78)G403-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:24894410},
      pmc          = {pmc:PMC4059031},
      doi          = {10.1186/1745-6215-15-204},
      url          = {https://inrepo02.dkfz.de/record/127974},
}